+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alexion Pharmaceuticals Inc (Alexion) discovers, develops and markets therapies based on complement biology and inhibition for rare diseases. The company’s portfolio spans complement inhibitors for the treatment of patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody positive patients. It also offers novel enzyme replacement therapies for patients with lysosomal acid lipase deficiency (LAL-D), hypophosphatasia (HPP), and ultra-rare metabolic disorders. Alexion is headquartered in New Haven, Connecticut, the US.

Alexion Pharmaceuticals Inc Key Recent Developments

Feb 04, 2021: Alexion reports fourth quarter and full year 2020 results
Jan 12, 2021: Alexion highlights commercial, clinical and financial progress at the 39th annual J.P. Morgan Healthcare Conference
Dec 14, 2020: AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn
Oct 29, 2020: Alexion reports third quarter 2020 results
Oct 06, 2020: Alexion highlights promising pipeline & distinguished rare disease capabilities at Virtual Investor Day

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Alexion Pharmaceuticals Inc - Key Facts
  • Alexion Pharmaceuticals Inc - Key Employees
  • Alexion Pharmaceuticals Inc - Key Employee Biographies
  • Alexion Pharmaceuticals Inc - Major Products and Services
  • Alexion Pharmaceuticals Inc - History
  • Alexion Pharmaceuticals Inc - Company Statement
  • Alexion Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Section 2 - Company Analysis
  • Company Overview
  • Alexion Pharmaceuticals Inc - Business Description
  • Product Category: Andexxa
  • Overview
  • Performance
  • Product Category: Kanuma
  • Overview
  • Performance
  • Product Category: Soliris
  • Overview
  • Performance
  • Product Category: Strensiq
  • Overview
  • Performance
  • Product Category: Ultomiris
  • Overview
  • Performance
  • Geographical Segment: Asia Pacific
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Others
  • Performance
  • Performance
  • Geographical Segment: Rest of World
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Alexion Pharmaceuticals Inc - Corporate Strategy
  • Alexion Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Alexion Pharmaceuticals Inc - Strengths
  • Alexion Pharmaceuticals Inc - Weaknesses
  • Alexion Pharmaceuticals Inc - Opportunities
  • Alexion Pharmaceuticals Inc - Threats
  • Alexion Pharmaceuticals Inc - Key Competitors

Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Alexion Pharmaceuticals Inc, Recent Deals Summary

Section 5 - Company’s Recent Developments
  • Feb 04, 2021: Alexion reports fourth quarter and full year 2020 results
  • Jan 12, 2021: Alexion highlights commercial, clinical and financial progress at the 39th annual J.P. Morgan Healthcare Conference
  • Oct 29, 2020: Alexion reports third quarter 2020 results
  • Oct 06, 2020: Alexion highlights promising pipeline & distinguished rare disease capabilities at Virtual Investor Day
  • Aug 25, 2020: Alexion Pharmaceuticals: Departure of directors or certain officer; election of directors
  • Aug 06, 2020: Alexion announces appointment of first Chief Diversity Officer
  • Jul 30, 2020: Alexion reports second quarter 2020 results
  • Jul 02, 2020: Alexion finalizes settlement with the U.S. Securities and Exchange Commission
  • Jul 02, 2020: SEC charges Alexion Pharmaceuticals with FCPA violations
  • Jun 17, 2020: Alexion Charitable Foundation announces first rare belonging grants

Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Alexion Pharmaceuticals Inc, Key Facts
  • Alexion Pharmaceuticals Inc, Key Employees
  • Alexion Pharmaceuticals Inc, Key Employee Biographies
  • Alexion Pharmaceuticals Inc, Major Products and Services
  • Alexion Pharmaceuticals Inc, History
  • Alexion Pharmaceuticals Inc, Subsidiaries
  • Alexion Pharmaceuticals Inc, Key Competitors
  • Alexion Pharmaceuticals Inc, Ratios based on current share price
  • Alexion Pharmaceuticals Inc, Annual Ratios
  • Alexion Pharmaceuticals Inc, Annual Ratios (Cont...1)
  • Alexion Pharmaceuticals Inc, Annual Ratios (Cont...2)
  • Alexion Pharmaceuticals Inc, Interim Ratios
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Alexion Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios

List of Figures
  • Alexion Pharmaceuticals Inc, Performance Chart (2016 - 2020)
  • Alexion Pharmaceuticals Inc, Ratio Charts
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Regeneron Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Biogen Inc
  • Arvinas Inc
  • Novartis AG
  • Genzyme Corp
  • Baxter International Inc
  • DepYmed Inc
  • Amgen Inc